Literature DB >> 7980747

Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.

P Bytzer1, J M Hansen, O B Schaffalitzky de Muckadell.   

Abstract

The recommended strategy for management of dyspepsia is empirical treatment with an H2-blocking drug, followed by endoscopy if the symptoms do not respond or recur. We compared two strategies for the management of dyspepsia--treatment based on the results of prompt endoscopy (group 1) and empirical H2-blocker treatment with diagnostic endoscopy only in cases of therapeutic failure or symptomatic relapse within 1 year (group 2). Eligible patients had symptoms severe enough to justify empirical H2-blocker therapy. Symptoms, drug consumption, and sick-leave days were assessed through monthly diaries. Patients with non-organic dyspepsia diagnosed by endoscopy did not receive ulcer drugs. Of 414 patients randomised, 373 completed 1-year follow-up. Organic disease was found at endoscopy in 68 (33%) of 208 group-1 patients (ulcer in 45). Endoscopy was done in 136 (66%) of 206 group-2 patients. Case selection for endoscopy was not improved by the empirical treatment strategy, since the diagnostic profile was the same as in group 1 and 40% of the expected ulcer cases remained undiagnosed. After 1 year there were no differences in symptoms or quality of life measures. The empirical treatment strategy in dyspepsia was associated with higher costs, due mainly to a higher number of sick-leave days and cost of ulcer drug use. Prompt endoscopy is a cost-effective strategy in dyspeptic patients with symptoms severe enough to justify the current practice of empirical H2-blocker treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7980747     DOI: 10.1016/s0140-6736(94)92023-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  52 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 2.  Approaches to uninvestigated dyspepsia.

Authors:  R H Jones
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  A 9 year prospective cohort study of endoscoped patients with upper gastrointestinal symptoms.

Authors:  Johanna I Westbrook; Anne E Duggan; John M Duggan; Mary T Westbrook
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 4.  ACG and CAG Clinical Guideline: Management of Dyspepsia.

Authors:  Paul Moayyedi; Brian E Lacy; Christopher N Andrews; Robert A Enns; Colin W Howden; Nimish Vakil
Journal:  Am J Gastroenterol       Date:  2017-06-20       Impact factor: 10.864

5.  Does endoscopy diagnose early gastrointestinal cancer in patients with uncomplicated dyspepsia?

Authors:  N Sundar; V Muraleedharan; J Pandit; J T Green; R Crimmins; G L Swift
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 6.  How should Helicobacter pylori positive dyspeptic patients be managed?

Authors:  N J Talley
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

7.  Over the counter H2 receptor antagonists. Serve only as expensive antacids.

Authors:  A C Douds; J D Maxwell
Journal:  BMJ       Date:  1994-10-29

8.  Management of dyspeptic patients by general practitioners and specialists.

Authors:  V Stanghellini; C Tosetti; G Barbara; B Salvioli; R De Giorgio; R Corinaldesi
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

9.  Treatment of gastro-oesophageal reflux disease in adults. Efficacy of surgery needs to be compared with that of proton pump inhibitors.

Authors:  O Chassany; J F Bergmann; C Caulin
Journal:  BMJ       Date:  1999-01-02

10.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.